New preclincial study confirms mechanism of action of Follicum’s novel tissue repair peptides
Follicum AB today announces that significant progress has been made in the company's development of new drug treatments for diabetes and other diseases. Within the framework of a preclinical research project, the interaction between one of Follicum's tissue-repairing peptide families and a specific receptor has been characterized in detail. This will help accelerate continued optimization work aimed at advancing the company's preclinical projects to the clinical phase and increases their attractiveness among potential commercial partners. Follicum's most advanced drug candidate, FOL-005, is